secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0000950170-22-002291
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia reports $484.1M 2021 net sales (+10% YoY); net loss narrows to $167.9M
-----------------------------------------------------------------------------

- Q4 2021 net product sales $130.8M (+8% YoY); full-year net sales $484.1M (+10% YoY).
- Q4 net loss $43.1M ($0.27/sh) vs. $66.8M ($0.42/sh) in Q4 2020; full-year loss $167.9M ($1.05/sh).
- Resubmitted sNDA for pimavanserin in Alzheimer's disease psychosis; Phase 3 Lavender trial of trofinetide in Rett syndrome positive.
- FY2022 guidance: NUPLAZID net sales $510-560M; R&D expense $355-375M; SG&A $360-380M.
- Cash and investments $520.7M at Dec 31, 2021, down from $632.0M a year earlier.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017022002291/0000950170-22-002291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017022002291/acad-20220228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer